跳至主要内容
临床试验/NCT02097511
NCT02097511已完成1 期

A Randomized, Open-label, Three-sequence, Three-period Crossover Study to Investigate The Effect of Anplag on the Disposition of Betaloc in Healthy Male Volunteers

Ajou University School of Medicine1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2013年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
9
试验地点
1
主要终点
Plasma concentration of Metoprolol and metabolites

研究概览

简要总结

This is a randomized, open-label, single & multiple-dose, three-sequence, three-period crossover study to investigate the effect of sarpogrelate hydrochloride on the disposition of metoprolol tartrate in healthy male volunteers

详细描述

Eligibility for participation of this study will be determined from demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 4 weeks before study drug administration. Subjects suitable for this study will be admitted to the Clinical Trial Center of Ajou University Medical Center on the day before dosing (Day -1).

On Day 1, Subjects will be dosed study drug (metoprolol tartrate 100 mg once a day only, or metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a day, sarpogrelate hydrochloride 100 mg three times a day pretreatment for three days and metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a day).

Pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12 hours after metoprolol tartrate 100 mg dosing.

After one week of washout period (Day 8), Subjects will be dosed study drug by crossover manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12 hours after metoprolol tartrate 100 mg dosing.

After one week of washout period (Day 15), Subjects will be dosed study drug by crossover manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12 hours after metoprolol tartrate 100 mg dosing.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •Healthy male subjects aged 20 - 45 years
  • •With in 20% of ideal body weight, {Ideal body weight=[height(cm)-100]*0.9}
  • •Agreement with written informed consent

排除标准

  • •Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal disease or mental disorder (Past history or present)
  • •Inadequate result of laboratory test (especially, AST/ALT > 1.25 x UNL, Total bilirubin > 1.5 x UNL)
  • •Positive reaction in the HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL test
  • •Taking OTC(Over the counter)medicine including oriental medicine within 7 days
  • •Clinically significant allergic disease (Except for mild allergic rhinitis and dermatitis seems to be not need for medication)
  • •Subject with known for hypersensitivity reaction to Metoprolol or Sarpogrelate
  • •Previous whole blood donation within 60 days or component blood donation within 30 days
  • •Previous participation of other trial within 90 days
  • •Continued taking caffeine (caffeine > 5 cup/day), drinking (alcohol > 30 g/day) and severe heavy smoker (cigarette > 1/2 pack per day)
  • •An impossible one who participates in clinical trial by investigator's decision including for reason of laboratory test result

研究组 & 干预措施

Sarpogrelate pretreatment and Metoprolol

Experimental

Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day

干预措施: Sarpogrelate pretreatment (Drug)

Sarpogrelate pretreatment and Metoprolol

Experimental

Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day

干预措施: Sarpogrelate (Drug)

Sarpogrelate pretreatment and Metoprolol

Experimental

Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day

干预措施: Metoprolol (Drug)

Sarpogrelate and Metoprolol

Active Comparator

Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day

干预措施: Sarpogrelate (Drug)

Sarpogrelate and Metoprolol

Active Comparator

Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day

干预措施: Metoprolol (Drug)

Metoprolol only

Active Comparator

Metoprolol Tartrate 100 mg once a day

干预措施: Metoprolol (Drug)

结局指标

主要结局

Plasma concentration of Metoprolol and metabolites

时间窗: upto 12 hours after Metoprolol Tartrate 100 mg dosing

Cmax (maximal plasma concentration) and AUC (area under the time-concentration curve) will be calculated from pharmacokinetic samplings

次要结局

  • Blood pressure and pulse rate changes(Upto 12 hours after Metoprolol Tartrate 100 mg dosing)

研究者

发起方
Ajou University School of Medicine
申办方类型
Other
责任方
Principal Investigator
主要研究者

Doo-Yeoun Cho

Assistant Professor

Ajou University School of Medicine

研究点 (1)

Loading locations...

相似试验